Anixa Biosciences (ANIX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application covering its chimeric antigen receptor-T cell technology. The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa’s innovative CAR-T approach. Anixa’s CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology. This patent, along with others, was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. Anixa’s CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences receives notice of allowance for new patent from USPTO
- Innovative Oncology Approaches and Strategic Partnerships Drive Buy Rating for Anixa Biosciences
- Anixa Biosciences to develop AI-guided cancer vaccines with Verdi Solutions
- Anixa Biosciences: Buy Rating Affirmed Amid Patent Approval and Clinical Trial Advancements
- Anixa receives notice of allowance from USPTO for ovarian cancer vaccine
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue